Alnylam Pharmaceuticals Overview
Alnylam Pharmaceuticals Target Price
Analysts' 12-month price predictions for ALNY.
Get informed when a big investor buys or sells
+ FollowShare Price
$267.47
Average Target Price
$431.00
61.1% upside
61.1% upside5 analysts in the last 4 months
High: $470 | Low: $370
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-10 | Morgan Stanley | $400 | 49.5% upside |  |
| 2026-07-09 | Raymond James | $468 | 75% upside | |
| 2026-06-29 | H.C. Wainwright | $470 | 75.7% upside | |
| 2026-05-01 | Morgan Stanley | $370 | 38.3% upside | |
| 2026-05-01 | Bernstein | $447 | 67.1% upside | |
| 2026-02-17 | Canaccord Genuity | $429 | 60.4% upside | |
| 2026-02-13 | Morgan Stanley | $360 | 34.6% upside | |
| 2026-02-13 | Bernstein | $451 | 68.6% upside | |
| 2026-02-13 | Chardan Capital | $425 | 58.9% upside | |
| 2026-02-12 | Stifel NicolausPaul Matteis | $444 | 66% upside | |
| 2026-01-30 | H.C. Wainwright | $510 | 90.7% upside | |
| 2026-01-20 | RBC Capital | $465 | 73.9% upside | |
| 2026-01-20 | Wells Fargo | $376 | 40.6% upside | |
| 2026-01-12 | Needham | $529 | 97.8% upside | |
| 2026-01-12 | Raymond JamesMartin Auster | $472 | 76.5% upside | |
| 2026-01-08 | Truist Financial | $530 | 98.2% upside | |
| 2026-01-06 | Bernstein | $491 | 83.6% upside | |
| 2025-12-15 | Leerink PartnersMani Foroohar | $351 | 31.2% upside | |
| 2025-12-11 | Stifel Nicolaus | $508 | 89.9% upside | |
| 2025-11-04 | H.C. WainwrightPatrick Trucchio | $570 | 113.1% upside | |
| 2025-10-31 | Barclays | $527 | 97% upside | |
| 2025-10-31 | OppenheimerLeland Gershell | $500 | 86.9% upside | |
| 2025-10-31 | Chardan CapitalKeay Nakae | $475 | 77.6% upside | |
| 2025-10-30 | UBS | $549 | 105.3% upside | |
| 2025-10-30 | Morgan StanleyMichael Ulz | $495 | 85.1% upside | |
| 2025-10-22 | Cantor Fitzgerald | $450 | 68.2% upside | |
| 2025-10-17 | Truist Financial | $535 | 100% upside | |
| 2025-10-06 | Morgan StanleyMichael Ulz | $475 | 77.6% upside | |
| 2025-10-06 | Stifel NicolausPaul Matteis | $495 | 85.1% upside | |
| 2025-09-05 | BMO CapitalKostas Biliouris | $470 | 75.7% upside | |
| 2025-07-29 | Raymond James | $370 | 38.3% upside | |
| 2025-07-21 | Truist FinancialDanielle Brill | $385 | 43.9% upside | |
| 2025-06-24 | BMO CapitalKostas Biliouris | $360 | 34.6% upside | |
| 2025-03-21 | Scotiabank | $338 | 26.4% upside | |
| 2025-01-07 | BernsteinWilliam Pickering | $310 | 15.9% upside | |
| 2024-10-24 | Canaccord GenuityWhitney Ijem | $336 | 25.6% upside | |
| 2024-10-01 | Canaccord GenuityWhitney Ijem | $366 | 36.8% upside | |
| 2024-09-27 | Bank of America SecuritiesTazeen Ahmad | $307 | 14.8% upside | |
| 2024-08-27 | BMO CapitalKostas Biliouris | $300 | 12.2% upside | |
| 2024-08-26 | RBC CapitalLuca Issi | $300 | 12.2% upside | |
| 2024-08-16 | Goldman SachsSalveen Richter | $370 | 38.3% upside | |
| 2024-07-08 | Canaccord GenuityWhitney Ijem | $357 | 33.5% upside | |
| 2024-06-28 | UBSEsther Rajavelu | $288 | 7.7% upside | |
| 2024-06-27 | RBC CapitalLuca Issi | $265 |  0.9% downside | |
| 2024-06-27 | Stifel NicolausPaul Matteis | $295 | 10.3% upside | |
| 2024-06-25 | Evercore ISILiisa Bayko | $260 | 2.8% downside | |
| 2024-06-25 | RBC CapitalLuca Issi | $250 | 6.5% downside | |
| 2024-06-24 | Morgan StanleyAndrew Galler | $250 | 6.5% downside | |
| 2024-06-24 | H.C. WainwrightPatrick Trucchio | $400 | 49.5% upside | |
| 2024-06-24 | Stifel NicolausPaul Matteis | $247 | 7.7% downside | |